Canaccord initiated coverage of Ocugen (OCGN) with a Buy rating and $12 price target The company has three clinical stage programs in rare and non-rare retinal diseases, the analyst tells investors in a research note. Canaccord views the data thus far in all three programs as “interesting.” It believes Ocugen’s data in Q3 could be a “de-risking event.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
- Ocugen initiated with an Outperform at Oppenheimer
- Ocugen price target raised to $22 from $15 at Lucid Capital
- Ocugen’s Gene Therapy Pipeline Dominates Earnings Call
- Ocugen: Late-Stage Retinal Pipeline and 2027–2028 Approval Catalysts Underpin Buy-Rated Risk‑Reward